Ganymed's IMAB362 Receives Orphan Drug Designation From FDA and EMA - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ganymed's IMAB362 Receives Orphan Drug Designation From FDA and EMA



Ganymed Pharmaceuticals AG, reported that  FDA and the European Medicines Agency (EMA) have granted orphan drug designation to IMAB362 for the treatment of pancreatic cancer. IMAB362 is a monoclonal antibody currently in Phase IIb clinical trial for gastroesophageal cancer.

IMAB362 is a monoclonal antibody selectively binding to the tight junction protein CLDN18.2, which is expressed in approximately 60% of primary and metastatic pancreatic cancers. CLDN18.2 is also expressed in up to 80% of gastroesophageal cancers as well as in other solid tumors. However, CLDN18.2 is absent from the vast majority of healthy tissues. This makes IMAB362 cancer cell selective with little or no effect on healthy cells and reduced risks of side effects.

Source: Ganymed Pharmaceuticals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here